# Short-term Embolization Using Gelatin Particles for FloW ModulAtion During Y90 Radioembolization

> **NCT06229080** · NA · COMPLETED · sponsor: **Next Biomedical Co., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Liver Cancer (Primary and Metastatic)

## Interventions

- **DEVICE:** NexGel

## Key facts

- **NCT ID:** NCT06229080
- **Lead sponsor:** Next Biomedical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-15
- **Primary completion:** 2025-01-20
- **Final completion:** 2025-07-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06229080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06229080, "Short-term Embolization Using Gelatin Particles for FloW ModulAtion During Y90 Radioembolization". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06229080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*